Compare Citius Pharmaceuticals Inc (CTXR) vs EOG Resources Inc (EOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs EOG Resources Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while EOG Resources Inc trades at $138.97 (market cap $73.51B). The key difference: EOG Resources Inc is far larger — about 5021.2× Citius Pharmaceuticals Inc's market cap, and EOG Resources Inc pays a 2.96% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | EOG | |
|---|---|---|
Market Cap | $14.64M | $73.51B |
Sector | Health | Energy |
52-Week High | $1.82 | $149.89 |
52-Week Low | $0.53 | $101.78 |
Enterprise Value | $10.86M | $77.97B |
Dividend Yield | — | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
EOG Resources trades at $139.61, up 4.11% with a bullish technical outlook. The stock shows strong profitability with a net margin of 23.39% and ROE of 18.19%, supported by consistent earnings beats. Valuation ratios like P/E of 13.73 and EV/EBITDA of 6.6 appear attractive relative to historical levels. Recent news highlights operational excellence and dividend stability, with Q2 2026 earnings anticipated on August 5, 2026.
The outlook remains positive with a consensus price target of $156.40, implying 12% upside. Risks include oil price volatility and elevated capital expenditures, but EOG's low-cost production and solid balance sheet provide resilience. Analyst sentiment is strongly bullish with no sell ratings, reinforcing the investment case for growth and income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →
